Furthermore, treatments of targeting expression of the VEGF/VEGFR2/Ras/ERK axis have been shown to exert anti-tumor roles, including sophoridine [17,18], usnic acid [19], apatinib [20,21], dovitinib [22], sorafenib [23] and sulforaphene plus photodynamic treatment [24]. The gene discussed is KDR; the disease is neoplasm.